Overview of dsm-firmenich's Share Repurchase Program
dsm-firmenich, a leading innovator in nutrition, health, and beauty, is making noteworthy strides through its aggressive share repurchase program. The company recently announced key details about its commitment to repurchasing ordinary shares, aimed at covering share plans and reducing capital. This strategic action could potentially enhance shareholder returns and underscores dsm-firmenich’s dedication to creating long-term value for its investors.
Program Details and Objectives
Initially unveiled on February 13, 2025, the program set forth a substantial plan to repurchase its ordinary shares with an aggregate market value of €1 billion. dsm-firmenich intended to reconcile this with an aim to amend its issued capital structure. On April 1, 2025, the company began executing its repurchase program with an allocation of €580 million. This amount included €80 million designated to satisfy commitments under the Group’s share-based compensation plans and €500 million aimed at reinforcing its capital structure.
Recent Progress in Share Repurchases
As part of the ongoing efforts, dsm-firmenich announced on June 27, 2025, that the repurchase program would be expanded to €1,080 million, following the successful sale of its stake in the Feed Enzymes Alliance. This move reflects the company's robust financial position and its proactive approach in returning capital to shareholders.
Market Activity
Between November 3 and November 7, 2025, dsm-firmenich bought back 530,000 shares at an average price of €70.03, amounting to a total investment of €37.1 million. To this date, the company has repurchased 11,627,500 shares, translating to a remarkable average price of €84.90 and a total expenditure of €987.2 million under this repurchase initiative.
Future Outlook for the Share Repurchase Program
The share repurchase program is anticipated to reach its culmination no later than January 30, 2026. This timeline indicates dsm-firmenich's strategic maneuvering within the stock market, reinforcing investor confidence and showing its readiness to act in favor of shareholder interests.
Investor Relations and Communications
dsm-firmenich maintains an open channel for inquiries from investors and media. For further clarification or insights regarding the share repurchase program, stakeholders can reach out to dsm-firmenich's investor relations team through the following email: investors@dsm-firmenich.com. Similarly, media inquiries can be directed at media@dsm-firmenich.com, ensuring comprehensive support for all interested parties.
About dsm-firmenich
dsm-firmenich plays a crucial role in the fields of nutrition, health, and beauty, developing and manufacturing essential nutrients and flavors that cater to a growing global population. With dual headquarters in Switzerland and the Netherlands, and operations spanning nearly 60 countries, the company garners over €12 billion in revenue. Employing a diverse workforce of nearly 30,000, dsm-firmenich is truly committed to making daily progress for billions of people worldwide.
Frequently Asked Questions
What is the share repurchase program by dsm-firmenich?
The share repurchase program is an initiative aimed at buying back ordinary shares to cover share plans and reduce capital, enhancing shareholder value.
How much has dsm-firmenich allocated for its share repurchase program?
The company initially set an aggregate value of €1 billion for its share repurchase, later increasing it to €1,080 million.
When does the current share repurchase program conclude?
The share repurchase program is expected to be completed by January 30, 2026.
How many shares have been repurchased so far?
dsm-firmenich has repurchased a total of 11,627,500 shares to date at an average price of €84.90.
Where can I find more information about the company?
For further details, you can visit dsm-firmenich’s official site at www.dsm-firmenich.com or reach out to their investor relations team.
